Posted by Michael Wonder on 23 Feb 2020
Esperion announces FDA approval of Nexletol (bempedoic acid) tablet, an oral, once-daily, non-statin LDL-cholesterol lowering medicine
21 February 2020 - Nexletol will be commercially available in the U.S. 30 March 2020.
Esperion announced today that the U.S. FDA approved Nexletol (bempedoic acid) tablet, an oral, once-daily, non-statin LDL-cholesterol lowering medicine.
Nexletol is indicated as an adjunct to diet and maximally tolerated statin therapy for the treatment of adults with heterozygous familial hypercholesterolemia or established atherosclerotic cardiovascular disease who require additional lowering of LDL-cholesterol.
